A major clinical debate in 2026 centers on the use of DBM versus Recombinant Human BMP (rhBMP-2). rhBMP-2 is a purely synthetic, extremely potent growth factor. While it is more powerful than DBM, it is also significantly more expensive and has been linked to "ectopic" bone growth (bone growing where it shouldn't) and severe swelling in the neck during cervical spine surgeries.
DBM is viewed as the "safer, natural" alternative. It contains a lower, more physiological dose of a wide array of growth factors rather than a massive dose of just one. Because it is derived from natural bone, it releases these factors more slowly over time, mimicking the body's natural healing cycle. In 2026, DBM remains the more cost-effective choice for $80$% of standard bone-grafting cases.